Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Latest News
December 19th 2024

Canadian Study Highlights Care Variability for Older Patients With MDS/AML

December 17th 2024

Researchers Characterize Defining Feature of Pediatric AML Subtype

December 16th 2024

Top 5 Most-Read ALL/AML Articles in 2024

December 7th 2024

Receiving ASCT After First CR May Improve Certain Outcomes in AML

November 30th 2024

New CPX-351 Data Underscore Complexity of Treating AML in Older Patients 

Video Interviews
View All
July 13th 2024

W-T7 Shows Encouraging Response Rate, Manageable Safety in Relapsed/Refractory T-ALL/LBL

More News

Doctor carrying documentation for patient care | image credit: Kanisorn - stock.adobe.com
November 29th 2024

Advent of Ponatinib for Ph+ ALL Expected to Influence New Guidelines

Kyle Munz
With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.
FDA Approval | image credit: gomixer - stock.adobe.com
November 26th 2024

FDA Approves Imatinib Oral Solution for Treatment of Various Cancers

Kyle Munz
The FDA approval marks the first oral solution indicated for patients with different forms of leukemia.
AML cells concept | image credit: sovova - stock.adobe.com
November 21st 2024

Study Reveals Leukemia Transplant Successes and Persistent Relapse Risks

Kimberly Rath, PharmD
Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.
FDA approval stamp | Image Credit: Surendra - stock.adobe.com
Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Kristi Rosa
Revumenib has been approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older.
Genes - CrazyJuke - stock.adobe.com
November 15th 2024

NUP98 Rearrangements Linked to Poor Outcomes in AML

Kimberly Rath, PharmD
Findings of a recent study indicate that NUP98 rearrangements can significantly impact outcomes in patients with acute myeloid leukemia (AML).
FDA approval stamp | Image credit: BHM-stock.adobe.com
November 8th 2024

FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia

Laura Joszt, MA
The chimeric antigen receptor T-cell therapy obecabtagene autoleucel received approval to treat patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia.
Tacrolimus | Image Credit: © MQ-Illustrations - stock.adobe.com
November 7th 2024

Tacrolimus Linked to Lower Acute GVHD Risk

Kimberly Rath, PharmD
Posttransplantation treatment with either tacrolimus or cyclosporine A results in favorable outcomes, but tacrolimus may be better at preventing severe graft-versus-host disease (GVHD), according to new study findings.
New therapies for AML and other blood cancers may be informed by the overexpression of 3 proteins | image credit: jovannig - stock.adobe.com
November 2nd 2024

New Work Highlights Proteins as Potential Novel AML Therapeutic Targets

Gayle Turim Dickstein
Three proteins—THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel targets for future therapies.
AML | Image Credit: © Andrey - stock.adobe.com
October 30th 2024

After HMA Resistance in AML, a New Possible Therapy Option

Gayle Turim Dickstein
When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase called TOPORS may help.
Blood smear AML | image credit: Chansom Pantip - stock.adobe.com
October 20th 2024

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

AJMC Contributor
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Rash is a common side effect of an idarucibin and cytarabine induction intervention for AML | image credit: Kittiphan - stock.adobe.com
October 16th 2024

Researchers Identify Potential Predictors of Rash During AML Induction Therapy

AJMC Contributor
The study showed that having pre-existing leukopenia and more favorable performance status was associated with a higher risk of rash.
Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML | image credit: Matthieu - stock.adobe.com
October 16th 2024

Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML

Jared Kaltwasser
Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the fms-like tyrosine kinase 3 (FLT3) gene.
AML cells | image credit: TheWaterMeloonProjec - stock.adobe.com
October 3rd 2024

New Study Further Illuminates PARP1 Expression in ALL, AML, CML With BCR::ABL1 p190+

Kimberly Rath, PharmD
Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical parameters.
Research graphic | Image Credit: © marikova-stock.adobe.com
September 20th 2024

Multidisciplinary Prehabilitation to Boost Outcomes in AML, MDS for Stem Cell Transplant

Kimberly Rath, PharmD
A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) offered an allogenic hematopoietic stem cell transplantation.
Acute myeloid leukemia | Image: St Jude Children's Research Center
September 19th 2024

Institute for Value-Based Medicine®: Speakers Use AML Studies to Illustrate Effects of Disparities, Neighborhood Stress on Outcomes

Kyle Munz
Coverage from the Institute for Value-Based Medicine session at Ohio State University. This article will appear in the October issue of Evidence-Based Oncology.
Risk stratification in AML could benefit from mutational scoring | image credit: faraktinov - stock.adobe.com
September 17th 2024

Mutational Score May Improve Risk Stratification of Certain Patients With AML

AJMC Contributor
The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years or older receiving lower intensity treatment (LIT), including the adoption of a mutation score that accounts for certain gene mutations.
AML | Image Credit: © Dzmitry - stock.adobe.com
September 9th 2024

Key Biomarker Monitoring Improves Outcomes in ASCT Recipients With AML, MDS

Karen Jacobson-Sive
Donor lymphocyte infusion, both alone and in combination with azacitidine, restored CD34 levels in two-thirds of patients with a baseline CD34 donor chimerism of less than 80%.
Enhanced image of leukemia | Image Credit: © freshidea - stock.adobe.com
September 6th 2024

Two Leukemia Stem Cell Subtypes Identified

Karen Jacobson-Sive
Researchers have discovered 2 leukemia stem cell subtypes with distinct epigenetic and transcriptional signatures.
Immunology word cloud | image credit: ibreakstock - stock.adobe.com
August 27th 2024

Researchers Identify Potential IO Targets in AML Through Surfaceome Analysis

AJMC Contributor
By analyzing the surface proteome of a wide-ranging sample of acute myeloid leukemia (AML) specimens, researchers identified potential antigens and primitive cell markers representative of AML supgroups.
AML cells | image credit: LASZLO - stock.adobe.com
August 17th 2024

AML Treatment Has Shifted Toward More Personalized Approach

AJMC Contributor
Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease.
Maria Amaya, MD, PhD
August 16th 2024

Real-World Outcomes Not Always Reflected in Clinical Trials: Dr Maria Amaya

Kyle Munz
Maria Amaya, MD, PhD, University of Colorado School of Medicine, explores discrepancies between real-world data and clinical trial outcomes, as well as her experience ensuring the reliability of real-world analysis.
ALL cancer cells in blood flow | Image Credit: © Laszlo - stock.adobe.com
August 15th 2024

Spontaneous Remission in Childhood Cancer Rare but Fleeting

Jared Kaltwasser
A case report suggests vigilance is required even when cancers like acute lymphoblastic leukemia appear to go into remission without explanation.
doc comforting patient | Image Credit: Seventyfour-stock.adobe.com
August 3rd 2024

Blinatumomab Boosts Survival in MRD-Negative BCP-ALL

Jared Kaltwasser
Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and relapse-free survival.
awareness of hematologic disorders | Image Credit: Orawan-stock.adobe.com
July 30th 2024

ActivinA Helps B-ALL Cells by Inducing Extracellular Vesicles

Jared Kaltwasser
A new study suggests inhibiting ActivinA might improve the efficacy of chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL).
pregnant woman who is too hot| Image Credit: Studio Romantic-stock.adobe.com
July 27th 2024

High Ambient Temperatures in Pregnancy Related to Childhood Leukemia Risk

Gayle Turim Dickstein
When the mercury outside ascends too high early in pregnancy, the risk of pediatric acute lymphoblastic leukemia may rise as well; results also show greater impacts on Latino populations.
acute leukemia | Image Credit: GoodIdeas-stock.adobe.com
July 22nd 2024

New Study Highlights Venetoclax Combo Efficacy in ALL

Kimberly Rath, PharmD
This new study evaluates the efficacy of monotherapies and venetoclax combination therapies in different T-cell acute lymphoblastic leukemia (ALL) cell lines.
AML cells | Image credit: Laszlo - stock.adobe.com
July 15th 2024

CPX-351 Effective in AML, Possibly With Reduced Cardiotoxicity vs Standard Anthracyclines

Karen Jacobson-Sive
Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity.
concept of a genetic mutation | Image Credit: © lucadp - stock.adobe.com
July 4th 2024

Certain Low-Prevalence Mutations May Be Strong Drivers in Pediatric ALL

AJMC Contributor
The researchers noted that most genomic analyses have traditionally focused on commonly mutated genes, which can pinpoint mutations occurring most frequently but does not account for the extent to which these mutations impact cancer cell survival and proliferation.
Survey graphic | Image Credit: Tierney-stock.adobe.com
July 1st 2024

In Acute Leukemia, Chance of Response Is Patient’s Top Concern

Jared Kaltwasser
Quality of life was also a top concern among patients when asked about their priorities if they experienced relapse or were refractory to therapy.
AML acronym | Image Credit: Natalya-stock.adobe.com
June 28th 2024

Review of Posttransplant Strategies for AML Relapse Prevention

Kimberly Rath, PharmD
Researchers review the latest developments, challenges, and ongoing research in posttransplant maintenance for acute myeloid leukemia (AML).
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo